Stock screenerAll disclosures →
EDGAR →
CGEM
Conviction 47HealthcareScan · Thu, Sep 24, 2026Cullinan Therapeutics, Inc. (CGEM) closed at $15.43 (-8.57%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 25, RS Rating 95, -32.8% from its 52-week high, +52.4% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).
CGEM$15.43-8.57%
ResistanceSupportVol 14Insider sellVol MA14 1.43M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Cullinan Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.cullinantherapeutics.com ↗
Price15.43
Change-8.57%
Gap-1.72%
Rel volume3.78×
Avg volume1.18M
Avg $ vol23.51M
SMA 2020.93
SMA 5019.71
SMA 20015.26
Price vs 50-21.75%
Price vs 200+1.05%
MA stackmixed
50/200 cross—
Supertrenddown · 20.11
RSI (14)25
MACD hist-0.65
MACD cross—
Stoch %K / %D8 / 28
ADX (14)27
+DI / −DI12 / 45
RSI divergence—
MACD divergence—
ATR %8.71%
ADR %6.08%
52w high22.95
52w low5.75
From 52w high-32.79%
Above 52w low+168.26%
New 52w highNo
SqueezeOff
Bollinger width32.91%
%B-0.30
Donchian pos7.66%
Donchian high22.96
Donchian low14.80
AVWAP (52w high)20.09
vs AVWAP high-23.24%
AVWAP (52w low)13.66
vs AVWAP low+12.89%
OBV trendDown
Chaikin MF (20)-0.07
Today vs 20d3.78×
Avg vol (14d)1.43M
Avg vol (20d)1.18M
Avg $ vol (20d)23.51M
Market cap992.67M
RS Rating95 / 99
RS 3m (vs SPY)-21.02%
RS 6m (vs SPY)-7.11%
RS line new highNo
Trend template4/8
Technical rank39.6
1 week-27.79%
1 month-32.79%
3 months-16.53%
6 months+9.71%
1 year+153.28%
YTD+52.42%
P/E-4.51
P/B2.43
P/S—
P/FCF-5.65
EPS-3.69
Div yield—
ROE-53.80%
ROA-60.44%
Debt/Eq—
Current8.42
EV/EBITDA-3.79
Gross margin—
Net margin—
Rev growth-100.00%
EPS growth-31.36%
Price target35.20
Target upside128.20%
Analyst ratingBuy
Institutional117.09%
Ent. value914.03M
Revenue0
Net income-50.61M
Gross profit—
Free cash flow-175.8M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out61.46M
Employees109
ListedFri, Jan 8, 2021
Free float47.04M
Float %79.6%
Short interest10.37M
Days to cover15.5d
Short volume70.8%
Squeeze score100 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.81 vs −$0.71
Last surprise-14.1% miss
Setup gradeC
Conviction47 / 100
Pattern quality—
Tech rank39.6 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance22.99
Support17.27
Days since event—
Candle confirm—
Financials as of Tue, Sep 30, 2025 · quarterly.
Recent news
- Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager ProgramsAdvfn · Thu, Sep 24, 2026
- Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager PortfolioYahoo Finance · Thu, Sep 24, 2026
- Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib DataYahoo Finance · Thu, Sep 24, 2026
- Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed?Yahoo Finance · Thu, Sep 24, 2026
- Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumYahoo Finance · Mon, Sep 21, 2026
Congress activity
Disclosed STOCK Act trades in CGEM
No recent disclosed trades by Congress in CGEM. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in CGEM · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Michaelson Jennifer Chief Scientific Officer · Common Stock · 2026-08-13 | Exercise | 30K | $129K | 2026-08-13 | 2026-08-14 |
Michaelson Jennifer Chief Scientific Officer · Common Stock · 2026-08-13 | Sell | 30K | $608K | 2026-08-13 | 2026-08-14 |
Michaelson Jennifer Chief Scientific Officer · Stock Option (Right to Buy) · 2026-08-13 | Exercise | 30K | — | 2026-08-13 | 2026-08-14 |
Michaelson Jennifer Chief Scientific Officer · Common Stock · 2026-07-06 | Exercise | 4K | $17K | 2026-07-06 | 2026-07-07 |
Michaelson Jennifer Chief Scientific Officer · Common Stock · 2026-07-06 | Sell | 8K | $143K | 2026-07-06 | 2026-07-07 |
Michaelson Jennifer Chief Scientific Officer · Stock Option (Right to Buy) · 2026-07-06 | Exercise | 4K | — | 2026-07-06 | 2026-07-07 |
Allen Andrew R Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 21.78K | — | 2026-06-16 | 2026-06-18 |
Doyle Mittie Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 21.78K | — | 2026-06-16 | 2026-06-18 |
Thistle Mary Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 25.32K | — | 2026-06-16 | 2026-06-18 |
Webster Stephen W Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 25.32K | — | 2026-06-16 | 2026-06-18 |
SEC filings
EDGAR filings in CGEM · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.